Overview

Biotech

AI-driven psychedelic drug design using their Osmanthus platform. Lead compound MSD-001 (5-MeO-MiPT) in Phase 1 trials for mental health disorders. $24M+ raised.

Visit Website
0
Open Roles

Open Positions

No open positions at this time

Clinical Pipeline

No clinical trials on record